Biotech stocks could be at a major turning point after FDA approval of the first gene editing drug using CRISPR technology to treat sickle cell disease. Gove…
CRSP Stock On Wild Ride After FDA’s Historic Approval. These Gene Editing Treatments Could Be Next
Posted in bioengineering, biotech/medical